Clinical trial
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With…
NCT00040144 · Alexion Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00040144 |
|---|---|
| Title | Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B |
| Official title | A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Collaborators | Achillion, a wholly owned subsidiary of Alexion Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | ACH126, 433 |
| Enrollment | 85 |
| Start date | Jul 1, 2002 |
| Completion | May 1, 2003 |
| First posted | Jun 25, 2002 |
| Last update posted | Feb 18, 2021 |
| Countries | Canada, China, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: